Salk Institute

Technologies Available for Licensing


S07014: Young

Non-Nucleoside Reverse Transcriptase Inhibitors
Novel NNRTIs, compounds and pharmaceutical compositions for reducing HIV infection and replication.


S07001: Young

A Novel Antitoxin and Vaccine Platform Based on Nodavirus VLPS
A novel, chimeric virus-like particle (VLP) capable of multivalent display of PA shows significant advantages over existing monovalent PA immunogens for anthrax toxin. Studies indicate VLP-PA complex may eliminate the need for lengthy immunization schedules by providing immunity after a single injection, and has potential to generate effective vaccines against other pathogens, including combination vaccines immunizing against multiple toxins.


Get Involved
Join our online community
Facebook    Facebook
Twitter    Twitter
YouTube    YouTube
RSS    RSS
Contact
Salk Institute for Biological Studies
Street: 10010 North Torrey Pines Rd
City: La Jolla, CA 92037
Email: webrequest@salk.edu
Phone: 858.453.4100
Charity Navigator Rating
© Copyright 2013 Salk Institute for Biological Studies About Scientists & Research News & Media Events Support